Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel

Docetaxel is a cornerstone treatment for metastatic, castration resistant prostate cancer (CRPC) which remains a leading cause of cancer-related deaths, worldwide. The clinical usage of docetaxel has resulted in modest gains in survival, primarily due to the development of resistance. There are curr...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Kharaziha, Pedram, Chioureas, Dimitris, Rutishauser, Dorothea, Baltatzis, George, Lennartsson, Lena, Fonseca, Pedro, Azimi, Alireza, Hultenby, Kjell, Zubarev, Roman, Ullén, Anders, Yachnin, Jeffrey, Nilsson, Sten, Panaretakis, Theocharis
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2015
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4673300/
https://ncbi.nlm.nih.gov/pubmed/25844599
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars